U.S. flag

An official website of the United States government

NM_000030.3(AGXT):c.116_117dup (p.Ala40fs) AND Primary hyperoxaluria

Germline classification:
Likely pathogenic (1 submission)
Last evaluated:
May 10, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001175458.10

Allele description [Variation Report for NM_000030.3(AGXT):c.116_117dup (p.Ala40fs)]

NM_000030.3(AGXT):c.116_117dup (p.Ala40fs)

Gene:
AGXT:alanine--glyoxylate aminotransferase [Gene - OMIM - HGNC]
Variant type:
Duplication
Cytogenetic location:
2q37.3
Genomic location:
Preferred name:
NM_000030.3(AGXT):c.116_117dup (p.Ala40fs)
Other names:
p.Ala40Glnfs*7
HGVS:
  • NC_000002.12:g.240868981_240868982dup
  • NG_008005.1:g.5237_5238dup
  • NM_000030.3:c.116_117dupMANE SELECT
  • NP_000021.1:p.Ala40fs
  • NC_000002.11:g.241808397_241808398insCA
  • NC_000002.11:g.241808398_241808399dup
  • NM_000030.2:c.116_117dupCA
  • NP_000021.1:p.Ala40fs
Protein change:
A40fs
Links:
dbSNP: rs180177166
NCBI 1000 Genomes Browser:
rs180177166
Molecular consequence:
  • NM_000030.3:c.116_117dup - frameshift variant - [Sequence Ontology: SO:0001589]

Condition(s)

Name:
Primary hyperoxaluria
Identifiers:
MONDO: MONDO:0002474; MedGen: C0020501; OMIM: PS259900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001339029Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Likely pathogenic
(May 10, 2022)
germlineclinical testing

PubMed (3)
[See all records that cite these PMIDs]

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Performance evaluation of Sanger sequencing for the diagnosis of primary hyperoxaluria and comparison with targeted next generation sequencing.

Williams EL, Bagg EA, Mueller M, Vandrovcova J, Aitman TJ, Rumsby G.

Mol Genet Genomic Med. 2015 Jan;3(1):69-78. doi: 10.1002/mgg3.118.

PubMed [citation]
PMID:
25629080
PMCID:
PMC4299716

Selected exonic sequencing of the AGXT gene provides a genetic diagnosis in 50% of patients with primary hyperoxaluria type 1.

Williams E, Rumsby G.

Clin Chem. 2007 Jul;53(7):1216-21. Epub 2007 May 10.

PubMed [citation]
PMID:
17495019
See all PubMed Citations (3)

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV001339029.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (3)

Description

Variant summary: AGXT c.116_117dupCA (p.Ala40GlnfsX7) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-05 in 247578 control chromosomes (gnomAD). This frequency is not higher than the estimated maximum expected for a pathogenic variant in AGXT causing Primary Hyperoxaluria Type 1 (0.0024), allowing no conclusion about variant significance.c.116_117dupCA has been reported in the literature in individuals affected with Primary Hyperoxaluria Type 1 (Coulter-Mackie_2005, Williams_2007, Williams_2015). These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Two ClinVar submitters have assessed the variant since 2014: one classified the variant as likely pathogenic and one as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Jan 13, 2025